Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2013 Nov 16

PMID 24232746

Citations 48

Authors

James H Tabibian

Jayant A Talwalkar

Keith D Lindor

Affiliations

Soon will be listed here.

Abstract

Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness.

Citing Articles

A Closer Look into Autoimmune Liver Diseases.

Filipovic B, Marjanovic-Haljilji M, Blagojevic D, Dragovic M, Krsmanovic E, Matovic A Int J Mol Sci. 2025; 26(5).

PMID: 40076490 PMC: 11899773. DOI: 10.3390/ijms26051863.

Genetically predicted gut microbiota mediate the association between plasma lipidomics and primary sclerosing cholangitis.

Zhou J, Zhu D, Xu Y, Chen C, Wang K BMC Gastroenterol. 2024; 24(1):158.

PMID: 38720308 PMC: 11080140. DOI: 10.1186/s12876-024-03246-3.

Investigating the shared genetic architecture between primary sclerosing cholangitis and inflammatory bowel diseases: a Mendelian randomization study.

Dong X, Gong L, Hong M, Pan J BMC Gastroenterol. 2024; 24(1):77.

PMID: 38373892 PMC: 10875759. DOI: 10.1186/s12876-024-03162-6.

Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis.

Kim Y, Hurley E, Park Y, Ko S Exp Mol Med. 2023; 55(7):1380-1387.

PMID: 37464092 PMC: 10394020. DOI: 10.1038/s12276-023-01042-9.

Absence of gut microbiota reduces neonatal survival and exacerbates liver disease in Cyp2c70-deficient mice with a human-like bile acid composition.

Sjoland W, Wahlstrom A, Makki K, Scholer M, Molinaro A, Olsson L Clin Sci (Lond). 2023; 137(13):995-1011.

PMID: 37384590 PMC: 10346113. DOI: 10.1042/CS20230413.

References

Pohl J, Ring A, Stremmel W, Stiehl A . The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. 2005; 18(1):69-74. DOI: 10.1097/00042737-200601000-00012. View

Lichtman S, Wang J, CLARK R . A microcholangiographic study of liver disease models in rats. Acad Radiol. 1995; 2(6):515-21. DOI: 10.1016/s1076-6332(05)80410-6. View

Shimizu M, Iwasaki H, Mase S, Yachie A . Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic. Case Rep Gastroenterol. 2012; 6(2):249-53. PMC: 3369409. DOI: 10.1159/000338834. View

Osnes T, Sandstad O, Skar V, OSNES M . Lipopolysaccharides and beta-glucuronidase activity in choledochal bile in relation to choledocholithiasis. Digestion. 1997; 58(5):437-43. DOI: 10.1159/000201480. View

Chen X, OHara S, LaRusso N . The immunobiology of cholangiocytes. Immunol Cell Biol. 2008; 86(6):497-505. PMC: 2652127. DOI: 10.1038/icb.2008.37. View

OMahony C, Vierling J . Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis. 2006; 26(1):3-21. DOI: 10.1055/s-2006-933559. View

Mimura Y, Sakisaka S, Harada M, Sata M, Tanikawa K . Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology. 1995; 109(6):1969-76. DOI: 10.1016/0016-5085(95)90765-3. View

Lichtman S, Keku J, CLARK R, Schwab J, Sartor R . Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology. 1991; 13(4):766-72. View

Landaverde C, Ng V, Sato A, Tabibian J, Durazo F, Busuttil R . De-novo cholangiocarcinoma in native common bile duct remnant following OLT for primary sclerosing cholangitis. Ann Hepatol. 2009; 8(4):379-83. View

10.

Olsson R, Bjornsson E, Backman L, Friman S, Hockerstedt K, Kaijser B . Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol. 1998; 28(3):426-32. DOI: 10.1016/s0168-8278(98)80316-4. View

11.

Tabibian J, Lindor K . Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. J Anal Oncol. 2020; 1(1):50-55. PMC: 6939639. DOI: 10.6000/1927-7229.2012.01.01.7. View

12.

Abarbanel D, Seki S, Davies Y, Marlen N, Benavides J, Cox K . Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2012; 33(2):397-406. PMC: 3565076. DOI: 10.1007/s10875-012-9801-1. View

13.

Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M, Quervain E . Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2012; 62(4):531-9. DOI: 10.1136/gutjnl-2012-302578. View

14.

Pollheimer M, Trauner M, Fickert P . Will we ever model PSC? - "it's hard to be a PSC model!". Clin Res Hepatol Gastroenterol. 2011; 35(12):792-804. DOI: 10.1016/j.clinre.2011.04.014. View

15.

Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D . A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009; 15(3):330-40. DOI: 10.1002/lt.21679. View

16.

OHara S, Tabibian J, Splinter P, LaRusso N . The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol. 2012; 58(3):575-82. PMC: 3831345. DOI: 10.1016/j.jhep.2012.10.011. View

17.

Tabibian J, Weeding E, Jorgensen R, Petz J, Keach J, Talwalkar J . Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013; 37(6):604-12. DOI: 10.1111/apt.12232. View

18.

DuPont A, DuPont H . The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol. 2011; 8(9):523-31. DOI: 10.1038/nrgastro.2011.133. View

19.

Tabibian J, Lindor K . Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol. 2013; 7(2):103-14. DOI: 10.1586/egh.12.80. View

20.

Tabibian J, Masyuk A, Masyuk T, OHara S, LaRusso N . Physiology of cholangiocytes. Compr Physiol. 2013; 3(1):541-65. PMC: 3831353. DOI: 10.1002/cphy.c120019. View